

Cosmetic Considerations in Dark-Skinned Patients

Sarawin Harnchoowong¹, Vasanop Vachiramom², Natthachat Jurairattanaporn²

¹Department of Dermatology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand; ²Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence: Natthachat Jurairattanaporn, Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand, Tel +66 2201 1141, Fax +66 2201 1211 Ext 4, Email natthachat.j.md@gmail.com

Abstract: For dermatologists, diversities of human races result in an opportunity to encounter patients with various skin types. Cosmetic procedures have gained more popularity and become more accessible over the past decades. Thus, the selection of appropriate treatment protocol for each patient becomes inevitable. This review will focus on basic knowledge and key points in performing safe cosmetic-related procedures in patients with dark-complexioned skin. In terms of structure and function of the skin, people of color have equal epidermal thickness, keratinocyte size and melanocyte number. However, they have more stratum corneum compaction, melanosome dispersion and melanocyte activity than fair skin individuals. Data regarding drug penetration and cutaneous irritation showed conflicting results. Superficial chemical peels and microdermabrasion can be done safely in dark-skinned patients. Medium-depth peel should be used with extreme caution. While deep-depth peel should be avoided at all times due to pigmentary and textural complications. Prolonged treatment interval, use of priming agents and sun protection are recommended. Injectable materials including botulinum toxin and soft tissue augmentation by hyaluronic acid filler can be done harmlessly in dark-skinned patients. Lasers and energy-based devices should be done with caution. Higher melanin dispersion and melanocyte activity acts as competitive chromophore. Pigmentary or textural changes can occur after aggressive treatment protocol. High energy setting, pulse stacking, short wavelength lasers and short treatment interval should be avoided in dark-skinned patients.

Keywords: complications, dark skin, energy-based devices, injectables, laser, skin of color

Introduction

Immigration of people with various racial profiles to different regions across the world leads to the surge of both racial and cultural diversity. This brings an enormous impact on medical practice across all medical specialties. Clinicians, including dermatologists, now have more opportunities to treat people with diversely-mixed shades of skin color from light to dark skin tone. Proper treatment regarding patient's skin color has now gained more interest.

Profound basic research and advance technology in cosmetic field has led to developments of novel treatments for various dermatological conditions. Cosmetic-related procedures include treatments with varying degree of invasiveness such as topical medications, chemical peels, microdermabrasion, injectables, lasers, and light-based devices, etc. Due to different mechanisms behind each treatment, clinicians should be able to choose appropriate treatment for each individual patient. Patient's skin condition, age or skin type are among factors to be considered. Moreover, clinical expertise is also crucial to achieve satisfactory results.

The difference between patients with light and dark skin tone is the amount of melanin dispersion in basal layer of the epidermis. Patients with skin of color have higher melanin content. This increases the risk of developing non-specific thermal injury. Though Caucasian patients may develop side effects after cosmetic procedures, side-effects in dark-skinned patients are found more frequently including hyperpigmentation, hypopigmentation, permanent depigmentation, textural change, hypertrophic scar and keloid.

Concerning the mixture of races, dermatologists should be aware of treating patients with different skin types to avoid preventable side-effects. Our review will focus on basic knowledge about how to perform cosmetic-related procedures safely in people of color including topical medications, chemical peels, microdermabrasion, injectable materials, lasers and light-based devices, and important patients' education.

Topical Medications

Concerning the epidermal thickness, Freeman et al and Thomson ML demonstrated that dark-skinned patients have equal thickness compared to fair-skinned patients.^{1,2} Wiegand et al conducted the study in 1974 comparing stratum corneum compaction between dark and fair skinned patients. They found that dark-skinned patients require more tape stripping to remove stratum corneum than fair skinned patients (average 16.6 (8–25) vs 10.3 (6–15) strips).³ Reed et al also found that patients with Fitzpatrick skin type (FPT) V to VI require more tape stripping than patients with FPT II to III.⁴

Rienertson et al conducted a study about chemical composition of human epidermal lipids in 1959. They found that dark-skinned patients have more lipid content in stratum corneum than fair-skinned patients.⁵ According to a study by Sugino et al, dark-skinned patients had lower ceramide level, compared to fair-skinned. Ceramide level was inversely correlated to transepidermal water loss (TEWL) but directly correlated to water content in epidermis. Moreover, in-vitro study also confirmed previous study results regarding TEWL. Incubated cells of dark-skinned patients showed a statistically significant difference in terms of TEWL more than cells from fair-skinned patients.⁶

According to previously mentioned studies, dark-skinned patients have more stratum corneum compaction. However, the issue of dark-skinned patients having less drug penetration than fair-skinned patients is still controversial. Wedig et al and Berardesca et al reported that African Americans have lower percutaneous absorption of dipyrithione, nicotines and fluocinolone acetonide than patients with lighter skin types.^{7,8} On the contrary, Wickrema-Sinha et al found no difference in percutaneous absorption of methyl nicotinate and diflorasone diacetate between dark- and fair-skinned patients.⁹ In conclusion, study results regarding drug absorption are controversial. The lower percutaneous penetration in certain medications may result from their specific absorption property or experimental error.

There were few researches about skin irritation. The results showed that patients of color have less susceptibility to skin irritation than fair-skinned patients. While objective measurement was done by measuring TEWL and microcirculation in the study by Berardesca et al and Wilson et al.^{10,11} They found that dark-skinned patients had higher susceptibility to skin irritation than lighter skin types. According to previous studies, concern about people of color having higher chance of developing skin irritation is still equivocal. Furthermore, studies reported dark-skinned patients tend to be more resistant to irritation than in fairer patients.

Patients with skin of color have a higher chance of developing certain skin reactions after using products. Plewig et al conducted a study in 753 dark-skinned patients. The study found that prolonged habitual use of hair pomade in people of color increases risk of pomade acne up to 70%. Pomade is composed of mineral oil and petrolatum jelly which are considered comedogenic substances.¹²

Kaidbey and Kligman found that dark-skinned patients have different cutaneous reaction after using topical coal tar. Fair-skinned patients had inflammatory reaction as papules of papulopustules occurs within a few weeks after exposure. Meanwhile, dark-skinned patients developed comedogenic eruption within 2 weeks without coexisting inflammation. People of color react to comedogenic compound by inducing hyperkeratosis more than disintegration of hair follicle.¹³

In conclusion, people of color are not different from people with lighter skin types in terms of epidermal thickness. However, stratum corneum compaction, certain lipid content, and spontaneous desquamation seem to be more pronounced than in white skin. Percutaneous absorption in dark skin type patient remains inconclusive. The structures and functions of epidermis are summarized in [Table 1](#).

Chemical Peels

Chemical peel works as an exfoliating agent that ablates partial skin thickness. Superficial chemical peel removes stratum corneum down to papillary dermis. Medium depth chemical peel exfoliates from papillary dermis to upper reticular dermis. The strongest one is deep depth chemical peel which penetrates from superficial epidermis to mid-reticular dermis.^{14–16} Regarding previously mentioned studies on skin irritation, objective measurement found that people with dark skin are prone to have more skin irritation than fair skin patients. As a consequence, dark-skinned patients are prone to have postinflammatory hyperpigmentation, hypopigmentation or scarring after performing chemical peel that occur more frequently in medium to deep-depth chemical peels.^{15,17,18}

Table 1 Overview of Structure and Function of Epidermis in People of Color

Structural and Functional Issues	Difference (Compared to Fair Skin People)
Structures	
Epidermal thickness	Equal
Corneocyte size	Equal
Stratum corneum compaction	Increased
Melanocyte number	Equal
Melanosome	Increased dispersion
Functions	
Lipid content	Increased
Desquamation	Increased
Ceramide level	Decreased
Transepidermal water loss	Increased
Drug absorption	Conflicting Data
Cutaneous irritation	Conflicting Data

Glycolic acid (GA) is the most commonly used chemical peel. It requires neutralizing agent to stop the peel from functioning. Clinical endpoint for GA peel is mild erythema. Blistering, vesiculation, blanching or excessive patient discomfort are the undesirable signs that clinician should monitor carefully. Burns et al demonstrated the additional benefit of 10% GA to a topical regimen of hydroquinone and tretinoin in the treatment of postinflammatory hyperpigmentation. Patients with FPT IV–VI receiving the glycolic peels had more rapid improvement, compared to hydroquinone and tretinoin alone.¹⁹ In the treatment of acne vulgaris, Wang et al reported that 35% and 50% GA peels significantly reduce comedones, papules and pustules and also decrease pore size. Only small numbers of patients (5.6%) had cutaneous adverse effects including postinflammatory hyperpigmentation, skin irritation and herpes reactivation.²⁰ Sarkar et al conducted a study in Indian patients with melasma. They compared topical Kligman formula with concomitant use of 30–40% GA peel with topical Kligman formula. The study result showed that combination group has faster MASI reduction than topical treatment alone.²¹ Trichloroacetic acid (TCA) is the combination of acetic acid and chlorine. It functions as self-neutralizing peel and causes coagulation of epidermal proteins and keratinocytes thereby creating frosting that cannot be wiped off as in salicylic acid (pseudofrost). Clinical endpoint for TCA peel is mild to moderate erythema or faint white frosting with patchy erythema. Moreover, Kalla et al conducted a study comparing 55–75% GA peel with 10–15% TCA peel in Indian patients with melasma (n = 100). They found that TCA group show greater improvement than GA group. On the other hand, TCA group also produced more side effects in TCA group.²² Kumari et al also conducted a split face study in 100 Indian patients with melasma by comparing 20–35% GA peel with 10–20% TCA peel on the contralateral side. They found that both groups show equal improvement rates. However, TCA group experienced more erythema and scaling more than GA side (35%).²³

Salicylic acid (SA) peel is a self-neutralizing peel. It has lipophilic property that can dissolve in sebum and penetrate into pilosebaceous unit. Clinical endpoint is mild erythema with white powdery residue (pseudofrost). The study regarding the use of salicylic acid peels in patient of color was conducted by Grimes PE. They studied the efficacy of 20–30% SA peel in dark-skinned patients (FPT V to VI) with melasma, acne and PIH. Results showed that pigmentary complications were found in a number of patients (16%). Hypopigmentation occurred within 7 days after procedure in one patient (4%). Hyperpigmentation occurred within 7–14 days in 3 patients (12%).²⁴ While in Asian skin, 30% SA was safe and effective for patients with FPT III–IV. Bae et al compared 30% SA to Jessner's peel (SA+ lactic acid + resorcinol) for acne treatment. Both treatments showed promising results in reducing acne lesions with mild adverse reactions. There was no postinflammatory hyperpigmentation or scarring reported in the study.²⁵ Concurrently, Dayal et al proved that 30% SA was more effective and safer in the treatment of acne vulgaris compared to Jessner's peel. Postinflammatory hyperpigmentation was reported in 5% of patients treated with SA, compared to 20% rate in Jessner's group.²⁶

Lactic acid (LA) peel is considered a peel with hydrating property. It forms lactate after application and acts as humectants on the skin. The split-face study compared the efficacy of 92% lactic acid peels and Jessner's peel for the treatment of melasma. Result showed no difference in terms of efficacy and side-effects between the two study groups. Sarkar et al summarized level of evidence and strength of recommendation for the use of chemical peeling agents in ethnic skin. GA peel is the only strength A. LA, SA, TCA, Jessner's peel is considered strength B. Phytic acid and pyruvic acid is strength C.¹⁷ Other than type of chemical peeling agents used, concentration is also the crucial determining factor of the depth of penetration. The higher the depth of penetration is, the more risks of developing side effects are.

Garg et al conducted the study in Indian patients with melasma (FPT IV–V). It demonstrated that the use of priming agents such as hydroquinone cream or retinoic acid cream before chemical peeling help to improve MASI score, prevent relapse, and decrease incidence of PIH after procedure more than groups without priming agents.²⁷

In conclusion, a superficial chemical peel such as glycolic acid is safe for patients with skin of color. The peeling should be started with low concentration and slowly titrated between visits. Medium-depth chemical peel should be avoided as much as possible while deep depth chemical peels should be avoided at all times. The recommendation toward chemical peeling in skin of color is shown in Table 2. Moreover, concomitant uses of priming agents like hydroquinone or tretinoin cream 2 weeks before procedure help improve the efficacy of chemical peel and decrease risk of developing PIH. Lastly, appropriate post-treatment care, sun avoidance, and adequate sunscreen application also play important roles in preventing side-effects in patients with dark skin tone.

Microdermabrasion

Microdermabrasion (MD) is a closed loop system using abrasive stimulus such as aluminum oxide or sodium chloride to ablate a superficial layer of the skin. Abrasive spent crystals and skin debris will be suctioned back by vacuum system.²⁸ Possible side effects from MD can occur in patients who have thin fragile skin, photodamaged skin, or patients who take antiplatelet agents. The common side effects are erythema, mild pain, minor abrasion and petechiae. The study concerning side effects of MD in dark skinned patients is limited. However, dark patients can do MD as frequent as fair skin patients with selective use of low power setting to avoid possible side effects.²⁹

Injectable Materials

Skin aging occurs from both intrinsic and extrinsic factors. Intrinsic aging occurs in all structures underneath the skin including soft tissues and bones. On the other hand, extrinsic aging results from chronic sun exposure. The study found that patients with dark skin type have slower onset of photodamage up to 10–20 years and less severity than fair skin patients. Aging change in patients of color usually manifests as facial aging more than photodamaged skin.³⁰

However, cosmetic-procedures that help improve aging process are the same between dark and fair-skinned patients. Botulinum toxin is still the first desirable option for wrinkle reduction. Filler injection will be the best option to correct

Table 2 Summary of Chemical Peels in Ethnic Skin

Peeling Agents	Superficial-Depth	Medium-Depth	Deep-Depth
Salicylic acid (SA)	SA 20–30%	N/A	N/A
Pyruvic acid (PA)	PA 40–70%	N/A	N/A
Lactic acid (LA)	LA 10–30%	N/A	N/A
Glycolic acid (GA)	GA 30–70%	GA 70% + 35% TCA	N/A
Jessner's solution	Jessner's solution	Jessner's solution + 35% TCA	N/A
Trichloroacetic acid (TCA)	TCA < 30%	TCA 35–50%	TCA >50%
Recommendation	Safe	Use with caution	Avoid

Abbreviation: N/A, not available.

facial volume loss. This review will particularly focus on the use of botulinum toxin and hyaluronic acid filler injection in dark skin complexion.

Botulinum Toxin

Botulinum toxin A (BT-A) and B (BT-B) are commercially available for cosmetic and therapeutic indications.³¹ However, BT-A is mainly used for cosmetic purposes which can be classified into onabotulinumtoxin A (onaBT-A), abobotulinumtoxin A (aboBT-A), incobotulinumtoxin A (incoBT-A), letibotulinumtoxin A (letiBT-A), daxibotulinumtoxin A (daxiBT-A), prabotulinum toxin A (proBT-A) or rimabotulinum toxin B (rimaBT-B). Both onaBT-A, aboBT-A, incoBT-A, daxiBT-A and praBT-A are approved for moderate to severe glabellar lines. Meanwhile onaBT-A has additional indication for axillary hyperhidrosis.³⁰ Botulinum toxin B has shorter action than BT-A. It was approved for the treatment of cervical dystonia.^{32,33} Botulinum toxin binds selectively and irreversibly to cholinergic nerve receptor and blocks the release of acetylcholine at neuromuscular junction. The blockage of nerve impulse prevents the targeted muscle from contraction. Treatment effects can be seen clinically after 5 to 7 days after onaBT-A injection and 2 to 3 days after aboBT-A. Duration of both agents typically lasts 3–6 months.³⁴

Facial wrinkles can be classified as static, dynamic or mixed. Static wrinkles are apparent even when the facial muscles are relaxed. Dynamic wrinkles are caused or aggravated by muscle contraction which are similar for all skin types. However, there are notable differences in skin physiology between patients with skin of color and patients with fair skin. These differences lead to greater tolerability to extrinsic aging factors, leading to delay and lesser degree in wrinkles development in people of color.³⁵ Dark skin patients develop facial lines at upper face more than perioral area. Moreover, patients with darker skin also develop brow ptosis and crow's feet later than fair skin type patients.^{36,37} Masseter hypertrophy becomes one of the major concerns especially in Asian patients who favor slim "V-shaped" facial structure.^{38,39} Glabellar lines pattern is different in Asian, compared to westerners, described by smaller mass, narrower and shorter corrugator muscles.^{40,41} Clinician should provide individualized treatment regimen that suits for each patient, based on patterns and severity of wrinkles.

Concerning the safety and efficacy of botulinum toxin A. Multiple studies have been done regarding the use of onaBT-A in Chinese, Japanese, African-American, Brazilian, Iranian and Korean populations. Results showed that there was no statistically significant difference in terms of efficacy and side effects between patients with different ethnicities.⁴² Moreover, there was no difference in the duration of action and dosage of toxin required for Asian skin despite more dermal thickness and collagen content in Asian skin.⁴³

Kane et al studied the efficacy of aboBT-A for glabellar line reduction in African American patients (20% of total study population). They found that this group of patients responded to aboBT-A better than general study population. After subgroup analysis, they also found that median duration of action was longer (117 days) compared to all study participants (109 days). However, there was greater incidence of aboBT-A-related ocular adverse events (6% vs 4%) but lower rate of injection site reaction (3% vs 5%) in African American patients than other ethnic groups.⁴⁴ Brandt et al also conducted a study by using aboBT-A for glabellar injection in non-white patients. They also found that dark skinned patients had better response than fair skin patients.⁴⁵ In terms of ocular adverse reactions, Brin et al conducted meta-analysis reporting that ocular adverse reactions including eyelid sensor disorder and eyelid edema were more common in Asian (Japanese and Chinese) than non-Hispanic white.⁴⁶ Additionally, prabotulinumtoxin A (praBT-A) is the new FDA-approved toxin for moderate to severe glabellar lines. Taylor et al reported the post-hoc analyses of the efficacy and safety regarding the color of the skin. Investigators grouped patients into skin of color (SOC, FPT IV–VI) and without SOC (FPT I–III). They further stratified patients into self-identified black and white patients. The results re-affirmed that efficacy, response rate and tolerability are similar between patients with SOC and without SOC. Dose adjustment is unnecessary for dark skin individuals.³⁵

Fillers

Soft tissue augmentation by filler is currently available worldwide for correcting of atrophic scarring, wrinkles, volume loss and contour defects. Internal sources of filling agents are autologous fat transfer or human collagen. Currently, numerous filling agents are commercialized. These include bacterial-derived hyaluronic acid (HA) filler, bovine, porcine collagen, calcium hydroxyapatite (CaHA), poly-L-lactic acid (PLLA), polynucleotide, etc. Currently, the most commonly used filler is HA derivatives.³⁰

Important factors to be considered in soft tissue augmentation are appropriate selection of filler type, depth of filler placement and techniques of filler injection. Smaller gel particles are suitable for superficial placement (mid to deep dermis) for the correction of static wrinkles and folds. Larger gel particles can be used to treat deeper, more severe areas by injecting into deep dermis to superficial subcutaneous tissue. However, it should be avoided in the lip area. Various injection techniques have been used such as linear threading, fan technique, cross hatching, towering technique, serial puncture, serial threading, etc.⁴⁷

Considering aging process other than facial wrinkles, volume loss can be troublesome in aging population. The most strikingly aging change of upper face region is volume loss especially in temporal area. Midfacial region changes are due to loss of elasticity, subcutaneous tissue, remodeling of cartilaginous and osseous structures beneath the skin. As a result, change of facial contour and laxity, including tear trough loss, mid-cheek hollowness, develops. Aging change of lower face, both muscle hyperactivity and volumetric loss of the mandibular region and adipose tissue play important roles to aging in this particular area. Volume loss in this area is obviously seen as pre-jowl hollowness and marionette lines.^{37,48}

In dark skin population, midfacial aging remains a common problem especially infraorbital hollowness, tear trough deformity and deepening of nasolabial folds. Skeletal morphology may contribute to this problem, both from infraorbital maxillary hypoplasia which can be found in African, Hispanic and Asian ancestry and also bone resorption due to aging process. Furthermore, sagging is more pronounced in dark-skin patients due to greater gravitational descent of facial soft tissue from the combination of heavy subcutis and weaker skeletal support. However, in dark skin patients, lips and perioral rhytids are less prominent. As African descents develop wrinkles mostly in the body of the lip below the vermilion border which occurs in response to volume depletion of the upper lip. On the other hand, the lower lip remains its same appearance.^{37,49} However, with more advanced age, skin of color patients (particularly African descent) have lip augmentation from age-associated volume loss more than patients without skin of color. For Asian population, lips are fuller than white population. Nevertheless, trend toward lips augmentation and reshaping increased significantly through recent years.

Patients with darker skin tend to have better stimulation of collagen production after filler procedures. Furthermore, they also demonstrate less thinning of collagen bundles and elastic tissue after treatment, as evaluated from histological study. Thereby, people of color might require fewer sessions of treatment than fair skin patients.⁵⁰

Filler injection in patients of color can be done efficaciously and safely according to the appropriate selection of filler type, injection techniques, and the plane of filler placement. Decreasing number of punctures, use of linear threading and mid dermal placement of HA filler are recommended to avoid disruption of dermo-epidermal junction, in order to decrease risk of possible complications.^{51,52} Glogau et al studied filler injection in patients of color. They found that 20% of dark-skinned patients had increased incidence of local adverse events including postinflammatory hyperpigmentation or bruising due to aggressive approach. This lead to penetration of dermo-epidermal junction (DEJ). Fan technique, rapid injection, high volume injection were listed as the possible causes.⁵³

Ethnic skin patients are considered to be 3 to 18 times more vulnerable to the development of keloidal formation.⁵² Hence, FDA approved 9 dermal fillers since 2003. These fillers had post-approval studies conducted specifically in patients with dark skin types (FPT IV to VI) in order to assess safety issues of dermal fillers. These included of keloid formation, dyschromia, hypertrophic scarring and hypersensitivity. The studies had been conducted by using HA and CaHA fillers. They showed similar rate of dyschromia between Caucasian and non-Caucasian population. There was no report of keloidal formation in the studies. However, one case developed symptomatic positive serum IgG antibody titer and mild hypertrophic scarring with HA fillers.^{54,55} Marmur et al conducted the study using CaHA for nasolabial fold correction in FPT IV to VI. They found no increased risk of developing hypertrophic scar, keloid or dyspigmentation after CaHA. Moreover, Lin YJ et al and Narins et al conducted studies of using PLLA for periorbital area (FPT II to III) and nasolabial fold correction (FPT I to VI), respectively. They also found no increased risk of hypertrophic scar, keloid or dyspigmentation as well.^{54,56,57}

Laser and Light-Based Devices

Since laser manufacturers are increasing in number, lasers and light-based devices are becoming more approachable to medical practitioners. Market shares and decrease in production costs make the price of laser treatment per session more

affordable to patients. There are many types of lasers and energy-based devices such as ablative lasers, fractional lasers, pigment-specific lasers, vascular-specific lasers, hair removal lasers etc.⁵⁸

People of color have higher melanin content and dispersion than people with lighter skin. Melanin has peak absorption range around 250–1200 nm which covers the range of visible light and near infrared spectrum. Patients with FPT VI absorb visible light more than patients with lighter skin (FPT I or II) up to 40% when use the same fluence and pulse duration. Therefore, patients with darker skin tone tend to have more non-specific thermal injury to epidermis. Common side effects after performing lasers and light-based devices in dark-skinned patients compose of postinflammatory hyperpigmentation (PIH), postinflammatory hypopigmentation, permanent depigmentation, textural change, focal atrophy of scarring.⁵⁹

Regarding general principle of treating dark-skinned patients, the lowest possible fluence to achieve target endpoint for each laser should be applied. Longer wavelength laser and larger spot size should be used to penetrate more deeply into the dermis and to avoid competitive absorption by endogenous melanin.

Ablative Resurfacing Lasers

Laser resurfacing technology improves several skin conditions in patients with all skin phototypes. However, several clinical studies demonstrated that carbon dioxide laser (CO₂) and erbium: yttrium-aluminum-garnet (Er:YAG) lasers can be used safely in dark skin complexions. However, general precaution should be applied to prevent possible complications.

Carbon dioxide laser has carbon dioxide gas as a medium which emits energy at 10,600 nm. The only chromophore is water. The water-containing tissue has thermal relaxation time around 1 millisecond. The laser can be emitted as a continuous wave and gated wave. Chopped wave CO₂ can be classified into superpulsed and ultrapulsed mode which develop less charring than continuous wave form.^{60,61}

Erbium:YAG emits energy at 2940 nm which shares the same chromophore (water) as CO₂ laser. However, Er:YAG laser is absorbed more superficially comparing to CO₂ laser. The clinician has to irradiate multiple passes to achieve similar depth as one pass of the CO₂ laser.⁶¹

Complications after performing ablative lasers include post-laser erythema, acne exacerbation, milia formation, post-treatment hyperpigmentation or hypopigmentation, Herpes reactivation or even scarring. Patients with dark skin phototype have higher risk of developing dyspigmentation or scarring after ablative lasers.⁶² Nanni et al reported incidence of post-laser hyperpigmentation after ablative CO₂ resurfacing at 37%. Majority of the PIH group were patients with darker skin tone. Hyperpigmentation was usually observed four weeks after the procedure and gradually resolved within months. Moreover, in some studies transient hyperpigmentation incidence was up to 68% to 100% among patients with the darkest skin phototypes (FPT III–VI).⁶³

Irradiating techniques and lasers parameters also play important roles in the development of post-operative complications. The use of high-energy pulsed CO₂ lasers (superpulsed or ultrapulse mode) produces single short pulses (less than 1 ms) thereby they create less tissue charring. Removal of desiccated tissue between laser passes is also crucial in order to decrease heat accumulation at the treatment site.⁶²

Proper pre- and post-treatment care should be applied to treatment plan especially in dark skin patients. Pretreatment with topical retinoic acid can help fasten re-epithelialization rates and reduce rates of melanin production after procedure. Moreover, it also helps reduce severity and duration of hyperpigmentation in darker skin tones. Strict sun avoidance and daily application of sunscreen should be initiated before and after procedures.⁶⁴

Fractional Lasers

The use of ablative laser skin resurfacing technology in facial rejuvenation and acne scar gives satisfactory results. However, prolonged down time and risk of potential side effects have led to decreased utilization of ablative laser resurfacing. The idea of fractional photothermolysis has become a new hope that provides efficacious clinical results and reduces post-treatment recovery period and possible side effects. Fractional lasers create columns of thermally denatured skin called microthermal treatment zones (MTZs) in the dermis with varying depths and widths. The healing process is

faster than conventional full ablative lasers due to migration of reservoir viable keratinocytes around islands of MTZ columns, creating rapid reepithelialization and faster recovery period.⁶⁵

Fractional resurfacing technology has been adapted to many types of lasers and energy-based devices to treat several skin conditions such as Er:YAG, CO₂, YSGG, Er:Glass or radiofrequency technology. Possible side effects of fractional lasers include prolonged erythema, wound infection, acne, milia, pigmentary change and scarring.⁶⁶

Patients of color have a high chance of developing postinflammatory hyperpigmentation (PIH) after lasers, especially ablative laser resurfacing. However, fractional laser resurfacing produced lower rate of PIH. According the study of Chan et al in 2007, overall PIH rate was 11.1% after fractional resurfacing 1540 nm erbium glass laser (Fraxel SR™, Reliant technology, Palo Alto, CA, USA). PIH rate was lower in patients who underwent high energy with lower density for acne scar condition. However, PIH rate was higher in patients who underwent the same density but with higher energy setting. To summarize, both energy setting and density of the treatment determine the risk of developing PIH after fractional resurfacing laser. Appropriate external cooling also plays important role in preventing PIH especially in small anatomical area such as perioral region.⁶⁷

Emmy et al found that patients with darker skin type experienced more pigmentary complications than fair skin type after fractional treatment. Patients with FPT II had 0.26% incidence of PIH, meanwhile patients with FPT III, IV and V had 2.6, 11.6 and 33% incidence of PIH respectively.⁶⁸ The study of Manuskiatti et al in 2009 found up to 92% incidence of transient hyperpigmentation after fractional carbon dioxide lasers in Thai subjects with FPT IV. The hyperpigmentation was completely resolved within 5 weeks.⁶⁹ While, the study of Wattanakrai et al in 2011 demonstrated side effects and complications of fractional 1550 nm erbium fiber laser (Finescan™; TNC Medditron Co., Ltd., Thailand) in Thai patients with FPT III–V. The study found that PIH was the most common side effect, at 2.2%, which mostly occurred after first treatment and progressively subsided with topical hydroquinone cream.⁷⁰

In conclusion, fractional laser resurfacing has lower rate of post-procedure complications than conventional ablative lasers. However, in patients with skin of color, physicians should use lower energy setting, fewer passes or treatment density, and appropriate skin cooling to prevent postinflammatory hyperpigmentation.

Pigment-Specific Lasers

The laser treatment of pigmented lesions is based on selective photothermolysis concept and the use of “Quality-switch, QS” technology to shatter pigments into small particles by photoacoustic mechanism within nanosecond range. Subsequent phagocytosis and lymphatic drainage occur. QS lasers used for pigmentary conditions include QS ruby (694 nm), QS alexandrite (755 nm) and QS Nd:YAG (532, 1064 nm). Other energy-based devices are long pulsed laser (ruby, alexandrite), intense pulsed light (IPL) or diode lasers. While, newly introduced picosecond lasers have faster rate of laser irradiation which cause pigment break down into smaller pieces and better results.⁶²

Pigment-specific lasers can be used to treat multiple pigmentary conditions. Pigmentary disorders can be classified into epidermal, dermal pigmentation or mixed conditions. Melasma is one of the most common pigmentary disorders among dark skin complexion, particularly in female patients. Energy-based devices that have been used to treat melasma are low fluence Q-switch Nd:YAG (1064 nm), IPL or even pulsed dye laser. Apart from pigmentary disease, tattoo removal is also a challenging and frequently-encountered problem in cosmetic practice. It requires multiple treatment sessions to achieve satisfactory result which often leads to various complications. Therapeutic endpoint of pigment-specific laser is immediate lesional whitening. Clinicians should sufficiently select fluence that cause such endpoint for the treated lesion without causing epidermal disruption, petechiae or pinpoint bleeding. Possible side-effects include hyperpigmentation, hypopigmentation or blistering which can occur exclusively in patients with skin of color (Figure 1). In this particular group of patients, clinicians should use fluence as low as possible to create optimal endpoint.⁷¹ Postlaser depigmentation can possibly occur, as presented in Figure 2.

Low fluence Q-switch 1064 nm Nd:YAG (LFQS) laser has been used to treat melasma. The exact mechanism is unclear however subcellular selective photothermolysis (SSP) theory may play an important role in fragmenting cytoplasmic melanin without disrupting cells. The histological assessment of facial melasma after LFQS showed decrease in melanin deposition in all layers of epidermis 1 week after laser irradiation.⁷² Considering the use of LFQS 1064 nm Nd:YAG or “laser toning” to treat melasma in patients with skin of color, pigmentary complication such as mottled hypopigmentation can occur after several sessions. The histologic study of hypopigmented area demonstrated



Figure 1 Segmental lentiginos in patient with Fitzpatrick skin type IV after single session of Q-switch neodymium-doped yttrium aluminum garnet (532 nm) on lower part of the lesion, notice the postinflammatory hyperpigmentation that occur on the lower half of the lesion.



Figure 2 Congenital melanocytic nevus in patient with Fitzpatrick skin type IV with permanent depigmentation after several sessions of Q-switch alexandrite laser (755 nm).

depletion in melanin content without the decrease in melanocyte number. Conflicting histological results were seen in the case series which showed that both melanocyte number and melanin were decreased in hypopigmented area.⁷³

In the study of Wattanakrai et al, mottled hypopigmentation was seen in 13.6% of patients after receiving 11 weekly sessions of LFQS 1064 nm Nd:YAG for melasma. All patients with mottled hypopigmentation in this study were FPT V.⁷⁴ Figure 3 shows patient with melasma developed this complication after several sessions of LFQS treatment. In order to avoid possible pigmentary complications in dark skin patients, clinicians should avoid excessive (more than 5, up to 10 treatments), too frequent (every week) or too high fluence LFQS procedure.⁷⁵

Tattoo is the placement of ink in the upper dermis. Dye content varies depending on the color of the tattoo. Removal of tattoo by laser can be done by nanosecond Q-switch lasers including QS ruby (694 nm), QS alexandrite (755 nm) or QS Nd:YAG (532, 1064 nm). Selection of laser is based on the color of tattoo. Multiple treatment sessions are usually required to achieve satisfactory results. Immediate erythema is not uncommon. After multiple sessions, long-term side effects such as hyper or hypopigmentation can occur, especially in dark skin patients (Figure 4).⁷¹

Nowadays, picosecond lasers can achieve faster satisfactory result compared to traditional nanosecond lasers. There were six clinical trials reporting local pigmentary change after picosecond laser irradiation. Post-treatment complications after 755 nm picosecond laser included both hyperpigmentation (2/12; 16.7%) and hypopigmentation (3/12, 25%). While, treatment with 1064 picosecond laser was found to have hypopigmentation (6.25%).⁷⁶ For other pigmentary conditions, picosecond laser showed trend toward decreased risk of developing postinflammatory hyperpigmentation,



Figure 3 Melasma in patient with Fitzpatrick skin type III with guttate hypopigmentation after multiple sessions of low fluence Q-switch neodymium-doped yttrium aluminum garnet (1064 nm).



Figure 4 (A) Black tattoo (Fitzpatrick skin type IV) with permanent depigmentation after multiple sessions of Q-switch neodymium-doped yttrium aluminum garnet (1064 nm), (B) Multicolor tattoo (Fitzpatrick skin type III) with permanent depigmentation after multiple sessions of Q-switch alexandrite (755 nm) for green tattoo and Q-switch neodymium-doped yttrium aluminum garnet (532 nm) for red tattoo.

compared to nanosecond laser.⁷⁷ Chan MWM. et al showed incidence of hypopigmentation in 3.6% and hyperpigmentation in 10.2% in solar lentigines treatment for patients with FPT III–IV with 532-nm picosecond laser.⁷⁸ Longer wavelength was preferred in lowering risk of PIH. Vachiramon et al reported PIH risk was lower in 755-nm picosecond laser (3.3%), comparing to 532-nm picosecond laser (6.7%), in the treatment of solar lentigines with similar efficacy.⁷⁹

Apart from conventional picosecond lasers, fractionated picosecond lasers are more frequently used in numerous conditions including dyspigmentation, acne scars, scars and skin rejuvenation. It induces laser-induced optical breakdown (LIOB) which leads to dermal collagen, elastin and mucin production. Kaewkes et al reported efficacy of fractional 1064-nm picosecond laser in treatment of abdominal striae distensae in patients with FPT IV–V. Postinflammatory hyperpigmentation occurred in 10% of participants, compared to 0% in other studies of patients with FPT II–III.^{80,81} For the treatment of acne scar, Manuskiatti et al reported 18% incidence of PIH after all treatment sessions.⁸² Chayavichitsilp et al conducted split-face study of acne scar treatment with fractional 1064-nm picosecond laser compared to non-ablative 1550-nm erbium fiber laser. Postinflammatory hyperpigmentation was observed in 6.67% after fractional 1064-nm picosecond laser treatment of acne in patients with FPT III–IV, compared to 10% in erbium treated side.⁸³ Other studies with fractional 755-nm and 1064-nm picosecond lasers for various conditions reported low incidence of PIH from 0–10.71%.^{84–86} Apart from postinflammatory hyperpigmentation, acneiform eruption was also reported. Palawisuth S. et al conducted study using fractional 1064-nm picosecond (Enlighten™, Cutera, Inc., Brisbane, CA, USA) in the treatment of acne scar of FPT III–IV patients. Acneiform eruption was found up to 14% of participants. No postinflammatory hyperpigmentation was reported.⁸⁷

Vascular Lasers

Vascular-specific lasers include a wide range of wavelength from 532 to 600 nm. The peak absorption of oxyhemoglobin is 577 nm. Pulsed dye laser (PDL) is the gold standard for vascular lesions. First generation of pulsed dye lasers emits yellow light at 585 nm which remains the gold standard for vascular lesion. However, the development of 595 nm pulsed dye laser allows clinician to achieve higher pulse duration and fluence. Other energy-based devices that can be used in vascular procedures are KTP 532 nm, IPL, long-pulsed alexandrite 755 nm, long-pulsed Nd:YAG (1064nm). Vascular lasers have been used to treat various skin conditions in patients with SOC such as port-wine stain, telangiectasia, spider angioma, postinflammatory erythema, keloid etc. Since vascular-specific laser has wavelength mostly within the range of melanin absorption, people with skin of color have higher risk of developing side effects after laser irradiation.⁸⁸

Pigmentary change after PDL session is common in dark skin patients. Transient hyperpigmentation can be reduced by appropriate skin cooling during and after laser irradiation. Postinflammatory hypopigmentation can also occur either temporary or permanently (Figure 5). Concerning 532 nm frequently doubled Nd:YAG and KTP lasers, non-specific epidermal injury can develop especially in patients with skin of color. Long-pulsed 1064 nm Nd:YAG laser is considered a safer option for patients with dark skin tone. Its wavelength of 1064 nm has deeper penetration and lower absorption by melanin in epidermis. Thereby, it creates less epidermal injury than other vascular lasers.⁶²



Figure 5 Nevus flammeus in patient with Fitzpatrick skin type III with permanent depigmentation after several sessions of pulsed dye laser (595 nm).

Hair Removal Lasers

Lasers and energy-based devices provide longer-term results compared to traditional hair removal procedures such as shaving or electrolysis. Currently used hair reduction lasers are long-pulsed Ruby (694 nm), long-pulsed alexandrite (755 nm), diode laser (800 nm), long-pulsed Nd:YAG (1064 nm) and IPL. The wavelength of light is limited to target melanin in hair follicles. Long pulse duration is applied (millisecond) to achieve thermal injury of the hair follicle. However, overlying epidermis contains melanin that competitively absorbs laser as well.⁸⁹

In order to avoid possible side effects, clinicians should modify appropriate parameter settings for patients with skin of color. Longer pulse duration, longer laser wavelength and appropriate surface cooling should be strictly applied. The long-pulsed 1064 nm Nd:YAG is preferred over other devices with shorter wavelength. This long wavelength is within the end of absorptive spectrum of melanin within hair follicles but too deep to be absorbed by epidermal melanin. The other applicable devices for dark-skin individuals are long-pulsed alexandrite lasers (755 nm), long-pulsed diode lasers (800–810 nm) and IPL (590–1200 nm).⁹⁰

Regarding the side effects after laser hair removal in patients with skin of color, the study of Lanigan SW showed that patients with FPT IV to VI (109 patients) has incidence of blistering at 14.9% with ruby laser and 5% with Nd:YAG laser. Incidence of hyperpigmentation was 9.9% with ruby laser and 2.1% with Nd:YAG laser. Overall incidence of side effects in skin type IV to VI treated with ruby laser was 3 times higher comparing with Nd:YAG laser (29.9% vs 9.4%).⁹⁰

Concerning the use of long-pulsed alexandrite laser for hair reduction, Eremia et al demonstrated that postinflammatory hyperpigmentation can occur in 10% and hypopigmentation in 2%.⁹¹ Moreover, Nanni et al and Alster et al also reported that pigmentary changes may occur in skin of color even when cooling was used.^{92,93} Vachiramon V et al studied in patient knowledge and attitudes on laser hair removal in 221 African American subjects. The study showed that many African Americans still have negative attitudes and knowledge towards laser hair removal. Approximately half of participants (55.2%) knew that dark-skinned patients can be treated with laser hair removal procedures.⁹⁴ Another prospective study was conducted in 480 patients across United Kingdom. It demonstrated that patients with darker skin types (FPT type IV to VI, 109 patients from total 480 patients) have higher incidence of hyperpigmentation from ruby laser (9.9%) than Nd:YAG laser (2.1%). Moreover, this group of patients also developed blistering from ruby laser treated group up to 14.9% which was more than Nd:YAG laser (5%).⁹⁰ For diode laser, Greppi I reported dyspigmentation after diode laser treatment in almost 40% (3 out of 8 patients with FPT V–VI).⁹⁵ Recently, Atta-Motte et al reported side effects in patients with various ethnicities from diode hair removal laser. Multiple side effects were reported in darker skin population ten times more frequent than in white and Asian populations. Skin sensitivity, hyperpigmentation and burns occurred statistically significant more in black and mixed races. Skin sensitivity was reported in almost a half of black patients compared to 17.24% in Asian and 23.62% in white. Hyperpigmentation was reported in 28% in black patients compared to 10.34% in Asian and 0% in white population. While burns occurred in 36% in black patients compared to approximately 10% in Asian and white groups.⁹⁶

Intense Pulse Light (IPL)

Intense pulse light (IPL) emits polychromatic broad bandwidth wavelengths from non-coherent filtered flash lamp. Cut-off filters selectively exclude the undesirable wavelength to treat specific target depending on clinical scenarios. The selected wavelength can be adapted to the patient's skin type. Higher filter wavelength helps to reduce the absorption of melanin and prevent complications such as erythema, blistering, crusting or hyperpigmentation in patients with dark skin types.⁹⁷

The studies regarding side effects and complications after IPL procedure are still limited. The most commonly observed reactions were transient erythema and edema which gradually resolved within 48 hours. The pain of the procedure increases with higher fluence and shorter pulses which usually accompanied by adverse effects such as erythema, edema, blistering, burning or dyspigmentation. It is important to ask the patient during the procedure to check the degree of pain, especially in patients with darker skin tone. Individualized parameter setting, for example, lower fluence, longer and splitted pulses should be applied. Furthermore, sufficient epidermal cooling is also essential to protect epidermis from being burned by the system. The cooling can be done by using cool gels, ice pack or external air cooling, etc.⁹⁸

Skin Tightening Devices

Photoaging includes both textural and pigmentary change of the skin. Furthermore, loss of skin and soft tissue integrity in combination with the pulling effect of gravity lead to the development of laxity especially in lower face area.³⁷ Various lasers and energy-based devices have been adapted to treat photoaging process, both superficial and deep layer of the skin. The use of devices to reverse the laxity process involves the technology that treat deep layer of skin such as infrared energy, radiofrequency and focused ultrasound devices. These technologies create a thermal energy to reticular dermis, subcutis or superficial muscular aponeurotic system (SMAS) to cause tissue contraction and remodeling while minimizing epidermal injury.⁹⁹

Infrared Skin Tightening

Infrared light produces volumetric heat at the dermis, causing immediate collagen contraction. As a result, collagen remodeling and new collagen synthesis subsequently occur. Chua et al studied the efficacy of infrared light in 21 patients with FPT IV to V. Infrared non-ablative heating device (TitanTM, Cutera, Inc., Brisbane, CA, USA) was used to treat face and neck laxity. The study showed satisfactory result with tolerable safety profiles. Pain and edema occurred temporary after the treatment. The reported side effect was superficial blistering which gradually subsided without scarring in all patients.¹⁰⁰

Radiofrequency

Radiofrequency (RF) has been used for tissue heating and tightening for both facial and body contouring. The depth of penetration is inversely proportional to the frequency used. Low frequency RF penetrates more deeply than high frequency RF. It can be delivered by using monopolar, bipolar, unipolar or multipolar devices. According to the latest development of fractional technology, fractional RF has been used to treat multiple skin conditions as well. Monopolar RF has the highest penetrating effect comparing to bipolar and unipolar devices. Patients have to be grounded by applying electrode pad. Bipolar devices deliver RF between 2 poles built into single handpiece. Unipolar device has single electrode and no grounding pad. It delivers RF in an omnidirectional field around the electrode.^{99,101}

RF energy does not target specific chromophore especially melanin in epidermis. Hence, RF is considered safe for all skin types. Kushikata et al studied the use of monopolar RF (Thermage[®], Solta Medical, Hayward, CA, USA) in 85 Japanese patients with FPT III–IV. It demonstrated that RF was effective for skin tightening in Asian face. However, there were reported two cases of blisters and secondary hyperpigmentation after RF treatment which may be due to improper contact of treatment tip.¹⁰²

In conclusion, RF is a safe technology that helps improve skin laxity for all skin types. Proper handling of RF devices is crucial to prevent possible side effects such as burn and blistering.

Focused Ultrasound

Ultrasound is an energy that can be delivered in focused pattern and penetrate deep to cause thermal coagulation points (TCPs) within tissue. Focused ultrasound has been used in medical field to do skin lifting. As also in RF, focused ultrasound has no specific chromophores. Thus, it is safe for all skin types. There are two major types of focused ultrasound include high-intensity focused ultrasound (HIFU) and microfocused ultrasound (MFU). HIFU uses high energy ultrasound to cause both thermal and cavitations to cause cell disruption and subsequent cell death, called thermomechanical process. Meanwhile, MFU uses much less ultrasound energy but creates small coagulation point (< 1 mm³) with greater heating than 60-degree Celsius to a depth of up to 5 mm.^{99,103}

The study regarding the safety of focused ultrasound is still limited especially with HIFU technology. This review will focus mainly on the use of MFU system. A commercially available MFU system is MFU with high-resolution ultrasound imaging which enables visualization of deep tissue planes to the depth of 8 mm (Ultherapy[®]; Merz Aesthetics, Raleigh, NC, USA). The device delivers energy to various depth, 1.5-mm, 3.0-mm and 4.5 mm focal depth with varying frequencies. The thermal injury is limited by short pulse duration and affects only deeper tissue plane. Due to the sparing of epidermal layer, cooling is unnecessary. MFU is considered safe procedure with no long-term side effects. The commonly found adverse effects include transient erythema (less than 24 hours), mild edema (last 2–4 weeks), dysesthesia (lasting 2–4 weeks) and bruising. Striated erythematous and edematous plaques can occur after treatment with superficial depth transducers, especially

1.5-mm focal depth transducer or from applying excessive gel on the skin. Less commonly observed side effects include transient inflammation of a superficial branch of the facial nerve which gradually subside within 2 to 4 weeks.¹⁰⁴ As previously mentioned, inappropriate application technique may cause severe epidermal injury and lead to dyspigmentation as demonstrated in [Figure 6](#).

The study regarding the safety of MFU system in patients with skin of color was conducted in 2011, Fifty-two patients with FPT III to VI was treated with MFU with visualization for facial and neck laxity. There were three adverse events, such as prolonged erythema, mild edema which most likely due to procedure or technique. There were no neurological events, acute skin damage, ulceration or abnormal pigmentation occurred in this group of patients.¹⁰⁵

As a result, MFU technology can be safely use for all skin types. However, clinician should learn how to use MFU properly especially the application and gel coupling technique. Energy setting should be lowered when treated with superficial depth transducer.

Patients' Education

Over the past decades, light skin tones have been worshiped more extensively than dark skin tones across all ethnic groups. A study concerning influence of skin tone and ratings of women's physical attractiveness had been done. The result showed that light-toned skin was rated more attractive than dark or tan skin tone from both male and female raters.¹⁰⁶

An epidemiological study of skin of color found that skin lightening is one the main reasons why women chose to use lightening agents (33%). African women use skin lightening agents 1.71 times more than Indian women. Prolonged abusive use of lightening agents to lighten the skin can lead to permanent complications such as ochronosis from hydroquinone, or skin atrophy from topical corticosteroids.¹⁰⁷ On the contrary, nowadays, some light-skinned individuals consider becoming tanned is more beautiful than the pale white skin. However, frequent tanning both from natural or artificial sources can increase risk of developing skin cancers.¹⁰⁸

Social and multimedia should encourage people to change attitudes towards darker shades of skin. Dark-skinned people can be beautiful and attractive as fair skin individuals. Sun protection is essential for all skin types to prevent premature aging and risk of developing skin cancers. Lasers can be done for dark skinned patients but with appropriate selection of lasers and parameter settings. Recommendation toward each procedures is summarized in [Table 3](#).



Figure 6 Dyspigmentation and scarring after high-intensity focused ultrasound technology in patient with Fitzpatrick skin type IV.

Table 3 Summary of Cosmetic Procedures Recommendation in Dark-Skinned Complexion

Cosmetic Procedures	Recommendation
Microdermabrasion	- Use of low-power setting
Botulinum toxin	- Same efficacy and tolerability without dose adjustment - Higher risk of ocular adverse reaction (eyelid edema) in Asian
Fillers	- Less aggressive approach and decreasing number of punctures - Use of linear threading and mid dermal placement
Energy-based devices	- Appropriate skin cooling during treatment - Adequate post-laser care eg sun protection and wound care
Ablative lasers	- Pre-treatment with retinoic acid and sunscreen to reduce PIH risk - Use of ultra-pulse mode to minimize tissue charring - Removal of desiccated tissue to decrease heat accumulation
Fractional lasers	- Use of lower energy, fewer passes and lesser density
Pigmented-specific lasers	- Avoiding excessive treatment sessions, frequency and pulse stacking - Choosing longer wavelength and optimal fluence to achieve end-point (Lowest possible) - Pre-treatment with hydroquinone to reduce PIH
Vascular lasers	- Preferred use of longer wavelength - Choosing optimal end-points (avoid too purpuric and blister end-points)
Hair removal lasers	- Preferred use of longer wavelength (1064-nm) - Choosing optical parameters and avoiding multiple passes - Keeping skin dry during treatment
Intense pulse light	- Choosing specific wavelength and higher cut-off filters - Using lower fluence, longer and splitted pulses
Skin tightening devices	- Similarity in safety and efficacy as in lighter skin

Abbreviation: PIH, postinflammatory hyperpigmentation.

Conclusion

Nowadays, physicians have to encounter with patients with different skin types. Patients with SOC or different ethnics have different anatomical and physiological factors. These may affect the efficacy and safety of cosmetic treatments. For topical medication, knowledge in effects of topical treatment against darker skin remain controversial. While chemical peeling can be safely done with selective superficial depth peel. Deeper peel should be used cautiously or avoided. Injectables, including botulinum toxin and fillers, are not approached similarly between darker and lighter skin individuals. However, injectables should be customized to each individual patients regarding their anatomical differences and problems. Lastly, for lasers and energy-based devices, clinicians should select appropriate parameters to avoid complications which is more common in darker skin individuals. Pre-treatment prevention, adequate cooling during procedures and post laser care are also essential factors. These procedures help to achieve safe and satisfactory outcomes.

Funding

This research received no external funding.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Freeman RG, Cockerell EG, Armstrong J, Knox JM. Sunlight as a factor influencing the thickness of epidermis. *J Invest Dermatol.* 1962;39(4):295–298. doi:10.1038/jid.1962.115
2. Thomson ML. Relative efficiency of pigment and horny layer thickness in protecting the skin of Europeans and Africans against solar ultraviolet radiation. *J Physiol.* 1955;127(2):236–246. doi:10.1113/jphysiol.1955.sp005252
3. Weigand DA, Haygood C, Gaylor JR. Cell layers and density of Negro and Caucasian stratum corneum. *J Invest Dermatol.* 1974;62(6):563–568. doi:10.1111/1523-1747.ep12679412
4. Reed JT, Ghadially R, Elias PM. Effect of race, gender and skin type on epidermal permeability barrier function. *J Invest Dermatol.* 1994;102:537.
5. Reinertson RP, Wheatley VR. Studies on the chemical composition of human epidermal lipids. *J Invest Dermatol.* 1959;32(1):49–59. doi:10.1038/jid.1959.11
6. Sugino K, Imokawa G, Maibach HI. Ethnic difference of stratum corneum lipid in relation to stratum corneum function. *J Invest Dermatol.* 1993;100:597.
7. Wedig JH, Maibach HI. Percutaneous penetration of dipyrithione in man: effect of skin color (race). *J Am Acad Dermatol.* 1981;5(4):433–438. doi:10.1016/S0190-9622(81)70105-1
8. Berardesca E, Maibach HI. Racial differences in pharmacodynamic response to nicotines in vivo in human skin: black and white. *Acta Derm Venereol.* 1990;70(1):63–66. doi:10.2340/00015555706366
9. Wickrema Sinha AJ, Shaw SR, Weber DJ. Percutaneous absorption and excretion of tritium-labeled diflorasone diacetate, a new topical corticosteroid in the rat, monkey and man. *J Invest Dermatol.* 1978;71(6):372–377. doi:10.1111/1523-1747.ep12556772
10. Berardesca E, de Rigo J, Leveque JL, Maibach HI. In vivo biophysical characterization of skin physiological differences in races. *Dermatologica.* 1991;182(2):89–93. doi:10.1159/000247752
11. Wilson D, Berardesca E, Maibach HI. In vitro transepidermal water loss: differences between black and white human skin. *Br J Dermatol.* 1988;119(5):647–652. doi:10.1111/j.1365-2133.1988.tb03478.x
12. Plewig G, Fulton JE, Kligman AM. Pomade acne. *Arch Dermatol.* 1970;101(5):580–584. doi:10.1001/archderm.1970.0400050084011
13. Kaidbey KH, Kligman AM. A human model of coal tar acne. *Arch Dermatol.* 1974;109(2):212–215. doi:10.1001/archderm.1974.01630020028006
14. Salam A, Dadzie OE, Galadari H. Chemical peeling in ethnic skin: an update. *Br J Dermatol.* 2013;169(Suppl 3):82–90. doi:10.1111/bjd.12535
15. Rullan P, Karam AM. Chemical peels for darker skin types. *Facial Plast Surg Clin North Am.* 2010;18(1):111–131. doi:10.1016/j.fsc.2009.11.010
16. Clark E, Scerri L. Superficial and medium-depth chemical peels. *Clin Dermatol.* 2008;26(2):209–218. doi:10.1016/j.clindermatol.2007.09.015
17. Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. *J Cutan Aesthet Surg.* 2012;5(4):247–253. doi:10.4103/0974-2077.104912
18. Vanaman M, Fabi SG, Carruthers J. Complications in the cosmetic dermatology patient: a review and our experience (Part 2). *Dermatol Surg.* 2016;42(1):12–20. doi:10.1097/01.DSS.0000479796.34703.94
19. Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. *Dermatol Surg.* 1997;23(3):171–174. doi:10.1111/j.1524-4725.1997.tb00014.x
20. Wang CM, Huang CL, Hu CTS, Chan HL. The effect of glycolic acid on the treatment of acne in asian skin. *Dermatol Surg.* 1997;23(1):23–29. doi:10.1111/j.1524-4725.1997.tb00003.x
21. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. *Dermatol Surg.* 2002;28(9):828–832. doi:10.1046/j.1524-4725.2002.02034.x
22. Kalla G, Garg A, Kachhawa D. Chemical peeling--glycolic acid versus trichloroacetic acid in melasma. *Indian J Dermatol Venereol Leprol.* 2001;67(2):82–84.
23. Kumari R, Thappa DM. Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma. *Indian J Dermatol Venereol Leprol.* 2010;76(4):447. doi:10.4103/0378-6323.66602
24. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. *Dermatol Surg.* 1999;25(1):18–22. doi:10.1046/j.1524-4725.1999.08145.x
25. Bae BG, Park CO, Shin H, et al. Salicylic acid peels versus jessner's solution for acne vulgaris: a comparative study. *Dermatol Surg.* 2013;39(2):248–253. doi:10.1111/dsu.12018
26. Dayal S, Amrani A, Sahu P, Jain VK. Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. *J Cosmet Dermatol.* 2017;16(1):43–51. doi:10.1111/jocd.12266
27. Garg VK, Sarkar R, Agarwal R. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels. *Dermatol Surg.* 2008;34(8):1032–1039. doi:10.1111/j.1524-4725.2008.34202.x
28. Shpall R, Beddingfield FC, Watson D, Lask GP. Microdermabrasion: a review. *Facial Plast Surg.* 2004;20(1):47–50. doi:10.1055/s-2004-822958
29. Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: an evidence-based review. *Plast Reconstr Surg.* 2010;125(1):372–377. doi:10.1097/PRS.0b013e3181c2a583
30. Davis EC, Callender VD. Aesthetic dermatology for aging ethnic skin. *Dermatol Surg.* 2011;37(7):901–917. doi:10.1111/j.1524-4725.2011.02007.x
31. Eleopra R, Tugnoli V, Quatrala R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. *Mov Disord.* 2004;19(Suppl 8):S53–9. doi:10.1002/mds.20010
32. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. *Dermatol Surg.* 2003;29(1):7–13; discussion. doi:10.1046/j.1524-4725.2003.29017.x
33. Flynn TC, Clark RE. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. *Dermatol Surg.* 2003;29(5):519–522. doi:10.1046/j.1524-4725.2003.29124.x
34. Carruthers A, Carruthers J. Botulinum toxin. In: Bologna JL, Jorizzo JL, Rapini RP, editors. *Dermatology*. New York: Elsevier Mosby; 2008:2381–2391.

35. Taylor SC, Grimes PE, Joseph JH, Jonker A, Avelar RL. PrabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines in adult patients with skin of color: post hoc analyses of the US Phase III clinical study data. *Dermatol Surg.* 2021;47(4):516–521. doi:10.1097/DSS.0000000000002864
36. Hexsel DM, Hexsel CL, Brunetto LT. Botulinum toxin. In: Grimes PE, Soriano T, Hexsel DM, Kim J, editors. *Aesthetics and Cosmetic Surgery for Darker Skin Types*. Philadelphia: Lippincott Williams & Wilkins; 2008:211–224.
37. Vashi NA, de Castro Maymone MB, Kundu RV. Aging differences in ethnic skin. *J Clin Aesthet Dermatol.* 2016;9(1):31–38.
38. Ahn J, Horn C, Blitzer A. Botulinum toxin for masseter reduction in Asian patients. *Arch Facial Plast Surg.* 2004;6(3):188–191. doi:10.1001/archfaci.6.3.188
39. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. *Dermatol Surg.* 2003;29(5):477–483. doi:10.1046/j.1524-4725.2003.29116.x
40. Quiñonez RL, Agbai ON, Burgess CM, Taylor SC. An update on cosmetic procedures in people of color. Part 2: neuromodulators, soft tissue augmentation, chemexfoliating agents, and laser hair reduction. *J Am Acad Dermatol.* 2022;86(4):729–739. doi:10.1016/j.jaad.2021.07.080
41. Jiang H, Zhou J, Chen S. Different glabellar contraction patterns in Chinese and efficacy of botulinum toxin type a for treating glabellar lines: a pilot study. *Dermatol Surg.* 2017;43(5):692–697. doi:10.1097/DSS.0000000000001045
42. Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. *Am J Clin Dermatol.* 2009;10(3):153–168. doi:10.2165/00128071-200910030-00002
43. Ahn KY, Park MY, Park DH, Han DG. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. *Plast Reconstr Surg.* 2000;105(2):778–784. doi:10.1097/00006534-200002000-00050
44. Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a Phase III, randomized, double-blind, placebo-controlled study. *Plast Reconstr Surg.* 2009;124(5):1619–1629. doi:10.1097/PRS.0b013e3181b5641b
45. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. *Dermatol Surg.* 2009;35(12):1893–1901. doi:10.1111/j.1524-4725.2009.01235.x
46. Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. *J Am Acad Dermatol.* 2009;61(6):961–70. doi:10.1016/j.jaad.2009.06.040
47. Beddingfield F, Kim J. Fillers in ethnic skin. In: Grimes PE, Soriano T, Hexsel DM, Kim J, editors. *Aesthetics and Cosmetic Surgery for Darker Skin Types*. Philadelphia: Lippincott Williams & Wilkins; 2008:225–240.
48. Tierney E, Sengelmann RD, Sattler G, Hanke CW. Soft tissue augmentation. In: Robinson JK, Hanke CW, Siegel DM, Fratila A, editors. *Surgery of the Skin*. Philadelphia: Mosby Elsevier; 2010:363–391.
49. Harris MO. The aging face in patients of color: minimally invasive surgical facial rejuvenation—a targeted approach. *Dermatol Ther.* 2004;17(2):206–211. doi:10.1111/j.1396-0296.2004.04021.x
50. Burgess C, Awosika O. Ethnic and gender considerations in the use of facial injectables: African-American patients. *Plastic Reconst Surg.* 2015;136(5 Suppl):28s–31s. doi:10.1097/PRS.0000000000001813
51. Odunze M, Cohn A, Few JW. Restylane and people of color. *Plast Reconstr Surg.* 2007;120(7):2011–2016. doi:10.1097/01.prs.0000287330.94038.63
52. Taylor SC, Burgess CM, Callender VD. Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator-blinded comparative trial. *Dermatol Surg.* 2009;35(Suppl 2):1653–1660. doi:10.1111/j.1524-4725.2009.01344.x
53. Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. *Dermatol Surg.* 2008;34(Suppl 1):S105–9. doi:10.1111/j.1524-4725.2008.34251.x
54. Marmur ES, Taylor SC, Grimes PE, Boyd CM, Porter JP, Yoo JY. Six-month safety results of calcium hydroxylapatite for treatment of nasolabial folds in Fitzpatrick skin types IV to VI. *Dermatol Surg.* 2009;35(Suppl 2):1641–1645. doi:10.1111/j.1524-4725.2009.01311.x
55. Grimes PE, Thomas JA, Murphy DK. Safety and effectiveness of hyaluronic acid fillers in skin of color. *J Cosmet Dermatol.* 2009;8(3):162–168. doi:10.1111/j.1473-2165.2009.00457.x
56. Narins RS, Baumann L, Brandt FS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. *J Am Acad Dermatol.* 2010;62(3):448–462. doi:10.1016/j.jaad.2009.07.040
57. Lin JY, Lin CY. Nonsurgical lower eyelid rejuvenation using injectable poly-d, l-lactic acid in Asian patients. *J Cosmet Dermatol.* 2022;21(10):4328–4331. doi:10.1111/jocd.15047
58. Shah S, Alster TS. Laser treatment of dark skin: an updated review. *Am J Clin Dermatol.* 2010;11(6):389–397. doi:10.2165/11538940-00000000-00000
59. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. *J Am Acad Dermatol.* 2002;46(2):S41–S62. doi:10.1067/mjd.2002.120790
60. Omi T, Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology. *Laser Ther.* 2014;23(1):49–60. doi:10.5978/islm.14-RE-01
61. Chapas AM, Geronemus RG, Hale EK. Energy-based treatment of the aging face for skin resurfacing: ablative and non-ablative lasers, photodynamic therapy of photoaging, and actinic damage. In: Robinson JK, Hanke CW, Siegel DM, Fratila A, editors. *Surgery of the Skin*. Philadelphia: Mosby Elsevier; 2010:549–561.
62. Bhatt N, Alster TS. Laser surgery in dark skin. *Dermatol Surg.* 2008;34(2):184–194. doi:10.1111/j.1524-4725.2007.34036.x
63. Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. *Dermatol Surg.* 1998;24(3):315–320. doi:10.1111/j.1524-4725.1998.tb04161.x
64. West TB, Alster TS. Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. *Dermatol Surg.* 1999;25(1):15–17. doi:10.1046/j.1524-4725.1999.08123.x
65. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. *Lasers Surg Med.* 2004;34(5):426–438. doi:10.1002/lsm.20048
66. Metelitsa AI, Alster TS. Fractionated laser skin resurfacing treatment complications: a review. *Dermatol Surg.* 2010;36(3):299–306. doi:10.1111/j.1524-4725.2009.01434.x
67. Chan HH, Manstein D, Yu CS, Shek S, Kono T, Wei WI. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. *Lasers Surg Med.* 2007;39(5):381–385. doi:10.1002/lsm.20512

68. Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. *Dermatol Surg*. 2008;34(3):301–305. doi:10.1111/j.1524-4725.2007.34062.x
69. Manuskiatti W, Triwongwanat D, Varothai S, Eimpunth S, Wanitphakdeedecha R. Efficacy and safety of a carbon-dioxide ablative fractional resurfacing device for treatment of atrophic acne scars in Asians. *J Am Acad Dermatol*. 2010;63(2):274–283. doi:10.1016/j.jaad.2009.08.051
70. Vaiyavatjamai P, Wattanakrai P. Side effects and complications of fractional 1550-nm erbium fiber laser treatment among Asians. *J Cosmet Dermatol*. 2011;10(4):313–316. doi:10.1111/j.1473-2165.2011.00585.x
71. Mariwalla K, Hruza GJ. Laser treatment of pigmented lesions and tattoos. In: Hruza GJ, Avram M, editors. *Lasers and Lights*. New York: Saunders Elsevier; 2013:20–32.
72. Hofbauer Parra CA, Careta MF, Valente NY, de Sanches Osorio NE, Torezan LA. Clinical and histopathologic assessment of facial melasma after low-fluence Q-switched neodymium-doped yttrium aluminium garnet laser. *Dermatol Surg*. 2016;42(4):507–512. doi:10.1097/DSS.0000000000000653
73. Wong Y, Lee SS, Goh CL. Hypopigmentation induced by frequent low-fluence, large-spot-size QS Nd:YAG laser treatments. *Ann Dermatol*. 2015;27(6):751–755. doi:10.5021/ad.2015.27.6.751
74. Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1064 nm) laser for the treatment of facial melasma in Asians. *Dermatol Surg*. 2010;36(1):76–87. doi:10.1111/j.1524-4725.2009.01383.x
75. Sugawara J, Kou S, Kou S, Yasumura K, Satake T, Maegawa J. Influence of the frequency of laser toning for melasma on occurrence of leukoderma and its early detection by ultraviolet imaging. *Lasers Surg Med*. 2015;47(2):161–167. doi:10.1002/lsm.22325
76. Reiter O, Atzmony L, Akerman L, et al. Picosecond lasers for tattoo removal: a systematic review. *Lasers Med Sci*. 2016;31(7):1397–1405. doi:10.1007/s10103-016-2001-0
77. Ungakornpairote C, Manuskiatti W, Junsuwan N, Wanitphakdeedecha R. A Prospective, split-face, randomized study comparing picosecond to Q-Switched Nd: YAG laser for treatment of epidermal and dermal pigmented lesions in Asians. *Dermatol Surg*. 2020;46(12):1671–1675. doi:10.1097/DSS.0000000000002486
78. Chan MWM, Shek SY, Yeung CK, Chan HH. A prospective study in the treatment of lentiginos in asian skin using 532 nm picosecond Nd:YAG laser. *Lasers Surg Med*. 2019;51(9):767–773. doi:10.1002/lsm.23103
79. Vachiramon V, Iamsuang W, Triyankulsri K. Q-switched double frequency Nd:YAG 532-nm nanosecond laser vs. double frequency Nd:YAG 532-nm picosecond laser for the treatment of solar lentiginos in Asians. *Lasers Med Sci*. 2018;33(9):1941–1947. doi:10.1007/s10103-018-2560-3
80. Kaewkes A, Manuskiatti W, Cembrano KA, Wanitphakdeedecha R. Treatment of abdominal striae distensae in Fitzpatrick skin types IV to V using a 1064-nm picosecond laser with a fractionated microlens array. *Lasers Surg Med*. 2022;54(1):129–137. doi:10.1002/lsm.23471
81. Fusano M, Galimberti MG, Bencini M, Guida S, Bencini PL. Picosecond laser treatment of striae distensae: in vivo evaluation of results by 3D analysis, reflectance confocal microscopy, and patient's satisfaction. *Lasers Surg Med*. 2021;53(9):1180–1185. doi:10.1002/lsm.23401
82. Manuskiatti W, Punyaratbandhu P, Tantrapornpong P, Yan C, Cembrano KAG. Objective and Long-term evaluation of the efficacy and safety of a 1064-nm picosecond laser with fractionated microlens array for the treatment of atrophic acne scar in Asians. *Lasers Surg Med*. 2021;53(7):899–905. doi:10.1002/lsm.23368
83. Chayavichitsilp P, Limtong P, Triyankulsri K, Pratumchart N. Comparison of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm picosecond laser and fractional 1550-nm erbium fiber laser in facial acne scar treatment. *Lasers Med Sci*. 2020;35(3):695–700. doi:10.1007/s10103-019-02891-5
84. Kwon HH, Yang SH, Cho YJ, et al. Comparison of a 1064-nm neodymium-doped yttrium aluminum garnet picosecond laser using a diffractive optical element vs. a nonablative 1550-nm erbium-glass laser for the treatment of facial acne scarring in Asian patients: a 17-week prospective, randomized, split-face, controlled trial. *J Eur Acad Dermatol Venereol*. 2020;34(12):2907–2913. doi:10.1111/jdv.16643
85. Huang CH, Chern E, Peng JH, Hsien-Li Peng P. Noninvasive atrophic acne scar treatment in Asians With a 755-nm Picosecond laser using a diffractive optic lens-A retrospective photographic review. *Dermatol Surg*. 2019;45(2):195–202. doi:10.1097/DSS.0000000000001669
86. Haimovic A, Brauer JA, Cindy Bae YS, Geronemus RG. Safety of a picosecond laser with diffractive lens array (DLA) in the treatment of Fitzpatrick skin types IV to VI: a retrospective review. *J Am Acad Dermatol*. 2016;74(5):931–936. doi:10.1016/j.jaad.2015.12.010
87. Palawisuth S, Manuskiatti W, Apinuntham C, Wanitphakdeedecha R, Cembrano KAG. Quantitative assessment of the long-term efficacy and safety of a 1064-nm picosecond laser with fractionated microlens array in the treatment of enlarged pores in Asians: a case-control study. *Lasers Surg Med*. 2022;54(3):348–354. doi:10.1002/lsm.23449
88. Rubin IK, Kelly KM. Laser treatments of vascular lesions. In: Hruza GJ, Avram M, editors. *Lasers and Lights*. New York: Saunders Elsevier; 2013:10–19.
89. Vejjabhinanta V, Nouri K, Singh A, Huo R, Charoenwad R. Laser for hair removal. In: Nouri K, editor. *Lasers in Dermatology and Medicine*. New York: Springer; 2012:91–101.
90. Lanigan SW. Incidence of side effects after laser hair removal. *J Am Acad Dermatol*. 2003;49(5):882–886. doi:10.1016/S0190-9622(03)02106-6
91. Eremia S, Li CY, Umar SH, Newman N. Laser hair removal: long-term results with a 755 nm alexandrite laser. *Dermatol Surg*. 2001;27(11):920–924. doi:10.1046/j.1524-4725.2001.01074.x
92. Nanni CA, Alster TS. Long-pulsed alexandrite laser-assisted hair removal at 5, 10, and 20 millisecond pulse durations. *Lasers Surg Med*. 1999;24(5):332–337. doi:10.1002/(SICI)1096-9101(1999)24:5<332::AID-LSM3>3.0.CO;2-2
93. Nanni CA, Alster TS. Laser-assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. *J Am Acad Dermatol*. 1999;41(2 Pt 1):165–171. doi:10.1016/S0190-9622(99)70043-5
94. Vachiramon V, McMichael AJ. Patient knowledge and attitudes on laser hair removal: a survey in people of color. *J Cosmet Dermatol*. 2011;10(3):197–201. doi:10.1111/j.1473-2165.2011.00567.x
95. Greppi I. Diode laser hair removal of the black patient. *Lasers Surg Med*. 2001;28(2):150–155. doi:10.1002/lsm.1031
96. Atta-Motte M, Załęska I. Diode laser 805 hair removal side effects in groups of various ethnicities - cohort study results. *J Lasers Med Sci*. 2020;11(2):132–137. doi:10.34172/jlms.2020.23
97. Rapp KK, Steiner R. Intense pulse light technology. In: Raulin C, Karsai S, editors. *Laser and IPL Technology in Dermatology and Aesthetic Medicine*. Berlin: Springer-Verlag Berlin Heidelberg; 2011:37–40.
98. Raulin C, Greve B, Grema H. IPL technology: a review. *Lasers Surg Med*. 2003;32(2):78–87. doi:10.1002/lsm.10145

99. Bogle MA, Kaminer MS. Non-surgical skin tightening. In: Hruza GJ, Avram M, editors. *Lasers and Lights*. New York: Saunders Elsevier; 2013:97–113.
100. Chua SH, Ang P, Khoo LS, Goh CL. Nonablative infrared skin tightening in Type IV to V Asian skin: a prospective clinical study. *Dermatol Surg*. 2007;33(2):146–151. doi:10.1111/j.1524-4725.2006.33032.x
101. Beasley KL, Weiss RA. Radiofrequency in cosmetic dermatology. *Dermatol Clin*. 2014;32(1):79–90. doi:10.1016/j.det.2013.09.010
102. Kushikata N, Negishi K, Tezuka Y, Takeuchi K, Wakamatsu S. Non-ablative skin tightening with radiofrequency in Asian skin. *Lasers Surg Med*. 2005;36(2):92–97. doi:10.1002/lsm.20136
103. Minkis K, Alam M. Ultrasound skin tightening. *Dermatol Clin*. 2014;32(1):71–77. doi:10.1016/j.det.2013.09.001
104. Fabi SG. Microfocused ultrasound with visualization for skin tightening and lifting: my experience and a review of the literature. *Dermatol Surg*. 2014;40(Suppl 12):S164–7. doi:10.1097/DSS.0000000000000233
105. Harris MO, Sundaram HA. Safety of microfocused ultrasound with visualization in patients with Fitzpatrick skin phototypes III to VI. *JAMA Facial Plast Surg*. 2015;17(5):355–357. doi:10.1001/jamafacial.2015.0990
106. Swami V, Furnham A, Joshi K. The influence of skin tone, hair length, and hair colour on ratings of women's physical attractiveness, health and fertility. *Scand J Psychol*. 2008;49(5):429–437. doi:10.1111/j.1467-9450.2008.00651.x
107. Dlova NC, Hamed SH, Tsoka-Gwegweni J, Grobler A. Skin lightening practices: an epidemiological study of South African women of African and Indian ancestries. *Br J Dermatol*. 2015;173(suppl 2):2–9. doi:10.1111/bjd.13556
108. Martin JM, Ghaferi JM, Cummins DL, et al. Changes in skin tanning attitudes. Fashion articles and advertisements in the early 20th century. *Am J Public Health*. 2009;99(12):2140–2146. doi:10.2105/AJPH.2008.144352

Clinical, Cosmetic and Investigational Dermatology

Dovepress

Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>